Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Fate Therapeutics (FATE) Non Operating Income (2016 - 2025)

Fate Therapeutics' Non Operating Income history spans 14 years, with the latest figure at $2.3 million for Q4 2025.

  • For Q4 2025, Non Operating Income fell 75.54% year-over-year to $2.3 million; the TTM value through Dec 2025 reached $11.4 million, down 52.57%, while the annual FY2025 figure was $11.4 million, 52.57% down from the prior year.
  • Non Operating Income reached $2.3 million in Q4 2025 per FATE's latest filing, down from $2.5 million in the prior quarter.
  • In the past five years, Non Operating Income ranged from a high of $11.3 million in Q3 2021 to a low of -$8.4 million in Q2 2021.
  • Average Non Operating Income over 5 years is $4.8 million, with a median of $4.3 million recorded in 2023.
  • Peak YoY movement for Non Operating Income: crashed 1415.59% in 2021, then surged 958.61% in 2022.
  • A 5-year view of Non Operating Income shows it stood at $761000.0 in 2021, then soared by 958.61% to $8.1 million in 2022, then plummeted by 50.93% to $4.0 million in 2023, then soared by 142.73% to $9.6 million in 2024, then crashed by 75.54% to $2.3 million in 2025.
  • Per Business Quant, the three most recent readings for FATE's Non Operating Income are $2.3 million (Q4 2025), $2.5 million (Q3 2025), and $2.9 million (Q2 2025).